The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Bristol-Myers Squibb‘s (BMS) investigational PD-1 immune checkpoint inhibitor nivolumab to treat patients with Hodgkin’s lymphoma (HL) after failure of autologous stem cell transplant and brentuximab.

Breakthrough therapy status is based on data from a group of patients with HL in the company’s ongoing Phase Ib trial of relapsed and refractory hematological malignancies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The breakthrough therapy designation is expected to speed-up the development and review of drugs for serious or life-threatening conditions.

"It is our goal to change the way patients live with cancer, especially in areas of high unmet medical need such as Hodgkin’s lymphoma, where patients may be underserved by currently available treatment options."

Bristol-Myers Squibb senior vice-president of development, oncology and immunosciences Michael Giordano said the breakthrough therapy designation granted by the FDA for nivolumab continues to support the development of innovative approaches designed to advance how cancer is treated.

"It is our goal to change the way patients live with cancer, especially in areas of high unmet medical need like Hodgkin’s lymphoma, where patients may be underserved by currently available treatment options," Giordano said.

See Also:

Nivolumab is an investigational, fully human PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T-cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is currently investigating whether by blocking this pathway, nivolumab would allow the immune system to resume its ability to recognise, attack and destroy cancer cells.

Hodgkin’s lymphoma (HL), also called as Hodgkin’s disease, is a cancer of the lymphatic system, which originates in white blood cells.

In the US, there is a five-year survival rate of 65% for advanced HL, which is one of two main types of lymphomas.

The company has a broad, global development programme to study nivolumab in multiple tumour types consisting of more than 35 trials as monotherapy or in combination with other therapies, which more than 7,000 patients have been enrolled worldwide.